LeMaitre Vascular, Inc. (NASDAQ:LMAT) Q1 2026 Earnings Call Transcript
Operator: Welcome to the LeMaitre Vascular's Q1 2026 Financial Results Conference Call. As a reminder to everyone, today's call is being recorded.
Lemaitre Vascular Inc (LMAT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Two Sigma Advisors John Overdeck And David Siegel | 281,978 | $30,783,538 | +735% | 0.02% |
| 2. | Ranger Investment Management Conrad Doenges (Cio) | 238,360 | $26,021,761 | -37% | 1.88% |
| 3. | 19,750,000 | $22,292,045 | -2% | 0% | |
| 4. | Driehaus Capital Richard Driehaus | 197,225 | $21,531,053 | 0.16% | |
| 5. | Renaissance Technologies Jim Simons | 138,502 | $15,120,263 | -24% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $31.06 | 30 | $931.73 | 181 | 2020-08-26 | Filing | |
| $25.28 | 151 | $3,817.05 | 151 | 2020-05-21 | Filing | |
| $28.35 | 7,074 | $200,512.53 | 43,557 | 2020-08-14 | Filing | |
| $5.50 | 4,000 | $22,000.00 | 3,927,163 | 2012-06-08 | Filing | |
| $5.34 | 2,000 | $10,680.00 | 3,917,163 | 2012-05-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $108.69 | 27,881 | $3,030,399.83 | 1,430,019 | 2026-05-08 | Filing | |
| $107.64 | 18,600 | $2,002,012.86 | 1,457,900 | 2026-05-07 | Filing | |
| $107.00 | 2,928 | $313,286.92 | 3,749 | 2026-05-08 | Filing | |
| $111.10 | 5,044 | $560,366.21 | 3,942 | 2026-05-07 | Filing | |
| $110.00 | 3,943 | $433,730.00 | 4,714 | 2026-05-07 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 963,706 | $92,477,275 | 0.57% | |
| 2. | 14,825 | $1,422,607 | 0.04% | |
| 3. | 2,430 | $233,183 | 0.04% | |
| 4. | 2,097 | $201,234 | 0.01% | |
| 5. | 793 | $76,096 | 0% |
News See All
Lemaitre Vascular (LMAT) is Strengthening Profitability in Vascular Disease Treatment
Conestoga Capital Advisors, an asset management company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here.
Is LeMaitre Vascular, Inc. (LMAT) A Good Stock To Buy Now?
Is LMAT a good stock to buy? We came across a bullish thesis on LeMaitre Vascular, Inc. on FluentInQuality’s Substack. In this article, we will summarize the bulls’ thesis on LMAT.
LeMaitre Vascular, Inc. (LMAT): A Bull Case Theory
We came across a bullish thesis on LeMaitre Vascular, Inc. on Compounding Quality’s Substack. In this article, we will summarize the bulls’ thesis on LMAT.
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Q4 2025 Earnings Call Transcript
Operator: Welcome to the LeMaitre Vascular Q4 2025 Financial Results Conference Call. As a reminder, today's call is being recorded. At this time, I would like to turn the call over to Mr.
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Q3 2025 Earnings Call Transcript
Operator: Hello. Good day. This is RJ, your conference operator today, and we welcome you to the LeMaitre Vascular, Inc. Q3 2025 Financial Results Conference Call.
LeMaitre Vascular, Inc. (LMAT) Gains Edge in Niche Vascular Device Market
LeMaitre Vascular, Inc. (NASDAQ:LMAT) is a medical device company specializing in products for peripheral vascular disease, affecting over 200 million people worldwide.
7 Hot Healthcare Stocks to Buy Right Now
The majority of Americans have experienced the annoyance of having their health insurance rejected, frequently without any recourse after contacting carriers by email and phone. Dr.
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Q2 2025 Earnings Call Transcript
Dorian LeBlanc: At this time, I would like to turn the call over to Mr. Dorian LeBlance, Chief Financial Officer of LeMaitre Vascular. Please go ahead, sir. Thank you, operator.
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Q1 2025 Earnings Call Transcript
Operator: Welcome to the LeMaitre Vascular First Quarter 2025 Financial Results Conference Call. [Operator Instructions]. I would like to turn the call over to Mr.
Hedge Fund Resource Center